Alkem Laboratories Q1 FY27 Earnings Call: Raises India Guidance to 12%, Targets CDMO Breakeven in 4-5 Quarters

Alkem Laboratories Ltd held its Q1 FY27 earnings call on August 14, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Growth of 11%; EBITDA Jumps 370 bps

• Revenue from operations of Rs.3,740 crores in Q1 FY 2026-2027, representing 11% YoY growth, with India sales at Rs.2,497 crores (+10.3%) and international at Rs.1,222 crores (+16%).
• EBITDA margin of 20.5% in Q1 FY 2026-2027, improving 370 bps YoY, driven by better product mix and favorable currency effects.
• Net profit declined 21.7% YoY in Q1 FY 2026-2027, attributed by management to a taxation impact; PBT grew 1.8%.
• R&D expenditure of 4% of revenue in Q1 FY 2026-2027, in line with the company's investment cycle.

Branded Generics Grow 12%; Trade Generics Flat; Outperformance vs IPM

• India business (excluding trade generics) reported price growth of 6%, new-launch contribution of 3%, and volume growth of 2% in Q1 FY 2026-2027 (Segment 11).
• Branded generics grew 12% in Q1 FY 2026-2027, while trade generics were flat YoY after double-digit growth in Q4 FY 2025-2026; management cited increased competition and stricter market practices (Segment 8).
• Alkem outperformed the Indian pharmaceutical market (IPM) by 100 bps in Q1 FY 2026-2027; acute segment grew 12.3% (vs IPM 10.1%, +220 bps) and chronic segment grew 17.9% (vs IPM 15.4%, +250 bps).
• Outperformance in seven key therapies in Q1 FY 2026-2027: anti-infectives 1.1x, gastro 1.2x, vitamins 1.4x, pain 1.8x, anti-diabetic 1.4x, respiratory 1.6x, and derma 1.6x vs market.
• Management cited sitagliptin patent expiry as a key driver of improved chronic-segment industry growth; Alkem is among the top three players in sitagliptin generics, though the current benefit remains small (Segment 11).
• Ortho business (ex-Oclutech) reported an EBITDA loss of Rs.5-7 crores in Q1 FY 2026-2027; management expects break-even within the next 12 months (by FY 2027-2028).
• Oclutech acquisition closed in July FY 2026-2027 (post-Q1); full-year FY 2026-2027 target is Rs.400 crores in sales with break-even EBITDA, below earlier guidance due to integration delays (Segment 7).

CDMO Investment Phase Continues; Daman OAI Under Resolution

• US revenue declined in constant-currency terms in Q1 FY 2026-2027, with no major volume expansion from products launched in the last 12–24 months; management maintained FY 2026-2027 US growth guidance at mid-to-high single digits, supported by currency tailwinds (Segment 12).
• Alkem's Daman facility received an OAI (Official Action Indicated) status; management initiated comprehensive corrective actions, does not expect impact on FY 2026-2027 business, and anticipates resolution within 6–12 months (Segments 4, 12).
• The Daman facility contributes 45% of US revenues; all products from that unit remain in active supply to the US market (Segment 7).
• US CDMO (Inzene) incurred Rs.60 crores of operating expenditure in Q1 FY 2026-2027; management guided full-year FY 2026-2027 CDMO opex of ~Rs.60 crores and does not expect break-even within the next 12 months (Segments 8, 11).
• CDMO break-even targeted in 4–5 quarters (by Q2/Q3 FY 2027-2028); annualised revenue of ~$25–30 million is required to reach break-even (Segments 5, 8).
• CDMO revenue of USD 30 million is expected to commence in FY 2027-2028; the facility is GMP compliant but not yet USFDA approved — approval will be triggered with a client site filing (Segments 8, 12).
• Five ANDA approvals received (one tentative) in Q1 FY 2026-2027; management confirmed the launch of Tonzabactam (Kinark) in the US in Q1 FY 2026-2027 (Segments 4, 9).

Gross Margin Guidance Held at 66.5–67%; Employee Costs Rise 16%

• Gross margins improved in Q1 FY 2026-2027 due to a better product mix (lower trade generic, higher prescription business) and favourable currency effects; management maintained full-year FY 2026-2027 gross margin guidance of 66.5% to 67%, citing expected API price increases that will impact subsequent quarters (Segment 13).
• Employee costs rose >16% in Q1 FY 2026-2027, driven by annual increments, the addition of 1,200 medical representatives in recent quarters, and CDMO operations (Segment 5).
• Other expenses increased due to the new CDMO business (operational from November 2025) and a ~10% higher dollar conversion rate on foreign subsidiary costs (Segment 5).
• Consolidated tax rate guidance for FY 2026-2027 revised to 30–32% (from an earlier standalone estimate of 27–28%), as losses in subsidiaries (SA, ND, US) where deferred tax assets are not recognised push the consolidated rate higher (Segment 10).
• Price erosion described as "close to flattish" and perceived to have bottomed out for the company (Segment 12).

India Guidance Raised; Biosimilar Pipeline Advances; CEO Search Underway

• India business revenue (trade generics + branded formulation) expected to grow close to 12% in FY 2026-2027, representing a ~100 bps improvement over prior guidance, driven by branded formulation performance (Segment 12).
• Trade generic growth guided to late single-digit for the next 1–2 years (FY 2026-2027 to FY 2027-2028); management prioritised execution and discipline over faster growth (Segment 10).
• Management stated that double-digit growth in non-US international markets is "quite sustainable"; Germany grew 35–40% (small base), while Chile and Australia also performed well (Segment 13).
• India biosimilar portfolio (7 products launched) generates annual sales of Rs.150 crores as of Q1 FY 2026-2027; backward integration has improved consolidated margins (Segment 7).
• Xgeva biosimilar launch in the EU expected within ~3 months (targeting Q3 FY 2026-2027); Denosumab (Prolia) biosimilar for the US missed its target approval date, pushing the timeline back by at least a few months (Segment 6).
• Oclutech EBITDA margins expected to improve by 7–8% YoY; management targets "a healthy EBITDA run-rate over 3–4 years" (Segment 7).
• CEO search is active; management expects the appointee to be in place by the next quarterly meeting (Q2 FY 2026-2027); no new acquisition plans in orthopedics or MedTech were disclosed (Segments 9, 10).